Skip to main content
SpringerLink
Log in

Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Background

Patients with multiple myeloma (MM) have increased risks of venous thromboembolism (VTE) and arterial thromboembolism (ATE). The risk of thrombosis differs among different treatment regimens. It is unknown if daratumumab could affect thrombosis risk.

Methods

A comprehensive search was conducted until April 2020. Events of VTE, including pulmonary embolism and deep venous thrombosis, as well as events of ATE, including acute ischemic stroke and myocardial infarction, were extracted from trials. In addition, events of thrombocytopenia and gastrointestinal (GI) bleeding were also extracted.

Results

Six trials were included in the meta-analysis. Daratumumab was associated with a lower risk of VTE compared with non-daratumumab regimen (Risk ratio [RR], 0.60; 95% confidence interval [CI], 0.40–0.91). The risk of ATE had no significant difference (RR, 0.80; 95% CI, 0.48–1.33). Daratumumab was also associated with a trend of higher risk of Grade 3/4 thrombocytopenia (RR, 1.14; 95% CI, 0.94–1.38), while the risk of GI bleeding was not significantly different (RR, 1.32; 95% CI, 0.38–4.65).

Conclusion

Daratumumab is associated with lower risk of VTE in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22.

    Article  CAS  Google Scholar 

  2. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012;17(Suppl 1):S177–S180180.

    Article  CAS  Google Scholar 

  3. Kristinsson SY, Pfeiffer RM, Bjorkholm M, Goldin LR, Schulman S, Blimark C, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–8.

    Article  CAS  Google Scholar 

  4. Leebeek FW. Update of thrombosis in multiple myeloma. Thromb Res. 2016;140(Suppl 1):S76–80.

    Article  CAS  Google Scholar 

  5. Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:653–63.

    Article  CAS  Google Scholar 

  6. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–23.

    Article  CAS  Google Scholar 

  7. Mushtaq M, Nam TS, Kim UH. Critical role for CD38-mediated Ca2+ signaling in thrombin-induced procoagulant activity of mouse platelets and hemostasis. J Biol Chem. 2011;286:12952–8.

    Article  CAS  Google Scholar 

  8. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31:150–3.

    Article  Google Scholar 

  9. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7:55–79.

    Article  Google Scholar 

  10. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    Article  CAS  Google Scholar 

  11. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.

    Article  CAS  Google Scholar 

  12. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–28.

    Article  CAS  Google Scholar 

  13. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–15.

    Article  CAS  Google Scholar 

  14. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet. 2019;394:29–38.

    Article  CAS  Google Scholar 

  15. Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood. 2020. https://doi.org/10.1182/blood.2020005288.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Al-Ani F, Bermejo JM, Mateos MV, Louzada M. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Thromb Res. 2016;141:84–90.

    Article  CAS  Google Scholar 

  17. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335:914–6.

    Article  Google Scholar 

  18. van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13–29.

    Article  Google Scholar 

  19. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, et al. Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. J Clin Oncol. 2019;37:8016.

    Article  Google Scholar 

  20. Baelum JK, Moe EE, Nybo M, Vinholt PJ. Venous Thromboembolism in Patients With Thrombocytopenia: Risk Factors, Treatment, and Outcome. Clin Appl Thromb Hemost. 2017;23:345–50.

    Article  CAS  Google Scholar 

  21. Plummer C, Driessen C, Szabo Z, Mateos MV. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9:26.

    Article  Google Scholar 

  22. Guan XH, Liu XH, Hong X, Zhao N, Xiao YF, Wang LF, et al. CD38 Deficiency protects the heart from ischemia/reperfusion injury through activating SIRT1/FOXOs-mediated antioxidative stress pathway. Oxid Med Cell Longev. 2016;2016:7410257.

    PubMed  PubMed Central  Google Scholar 

  23. Ishak J, Dimopoulos MA, Weber D, Knight RD, Shearer A, Caro JJ. Declining Rates of Adverse Events and Dose Modifications with Lenalidomide in Combination with Dexamethasone. Blood. 2008;112:3708.

    Article  Google Scholar 

  24. Leleu X, Gay F, Flament A, Allcott K, Delforge M. Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? Ann Hematol. 2018;97:387–400.

    Article  CAS  Google Scholar 

  25. Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety analysis of five randomized controlled studies of daratumumab in patients with multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2020. https://doi.org/10.1016/j.clml.2020.04.004.

    Article  Google Scholar 

Download references

Acknowledgements

None

Author information

Authors and Affiliations

  1. Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Dr, Cleveland, OH, 44109, USA

    Jiasheng Wang & Yeseong Kim

Authors
  1. Jiasheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeseong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design: JW. Data collection, assembly, and analysis: JW, YK. Manuscript writing: All authors. Final approval of manuscript: All authors.

Corresponding author

Correspondence to Jiasheng Wang.

Ethics declarations

Conflicts of interest

The authors declare no conflicts of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 273 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Kim, Y. Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. Int J Hematol 112, 650–657 (2020). https://doi.org/10.1007/s12185-020-02954-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02954-2

Keywords

Search

Navigation